Why has immune “checkpoint” therapy failed in most clinical trials?
Cancer immunotherapy targeting the PD-1/PD-L1 pathway has demonstrated efficacy across a range of common solid tumors and some hematopoietic malignancies. Despite these groundbreaking successes, the clinical development of other ‘checkpoint inhi…